Skip to content
TrialScanner

NCT02777931

Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD

Phase 2/Phase 3CompletedAVTXLead

Registry record

Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Conditions
Attention Deficit Disorder With Hyperactivity
Primary completion
Feb 10, 2017Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02777931 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.